PMID- 16143232
OWN - NLM
STAT- MEDLINE
DCOM- 20060530
LR  - 20131121
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 24
IP  - 9
DP  - 2005 Sep
TI  - First clinical experience with the Incor left ventricular assist device.
PG  - 1188-94
AB  - BACKGROUND: The Incor (Berlin Heart AG, Germany) is a small (200 g), implantable, 
      magnetically accentuated axial flow pump (non-pulsatile flow) designed to support 
      the left ventricle for extended periods of time. We report on the first 
      single-center clinical experience with this device. METHODS: The Incor was 
      studied in 15 consecutive patients (10 men, 5 women), 24 to 59 years of age. 
      Underlying heart disease was end-stage ischemic heart disease (n = 5), acute 
      myocardial infarction (n = 4), dilated cardiomyopathy (n = 3), acute myocarditis 
      (n = 2) and Chagas disease (n = 1). All patients were in New York Heart 
      Association (NYHA) Class IV heart failure. Four patients had prior open heart 
      surgery. Implantation via cannulation of the left ventricular apex and the 
      ascending aorta was elective in 6 patients and on an emergency basis in 9. 
      RESULTS: No early bleeding complications were seen, but late bleeding occurred in 
      4 patients. Minor cerebral thromboembolic events with transient neurologic 
      symptoms occurred in 3 patients; severe stroke had to be treated in 1 patient. 
      Systemic emboli were seen in 2 patients. Thrombus-related pump dysfunction was 
      suspected in 3 patients, and managed by intensifying anti-coagulation. Five 
      patients were successfully transplanted after a support interval of 90 to 156 
      days; 1 patient could be weaned from the system after 171 days. Six patients died 
      during support, 9 to 63 days after device implantation. The remaining 3 patients 
      are still under support, with excellent quality of life. CONCLUSIONS: The Incor 
      is a left ventricular assist device (LVAD) with transplant and adverse event 
      rates comparable to those of other modern ventricular support devices. Its 
      advantages include the small pump chamber, the virtual absence of device-related 
      infections, and the extraordinary convenience during implantation and 
      explantation.
FAU - Schmid, Christof
AU  - Schmid C
AD  - Department of Thoracic and Cardiovascular Surgery, University Hospital, Muenster, 
      Germany. schmid@uni-muenster.de
FAU - Tjan, Tonny D T
AU  - Tjan TD
FAU - Etz, Christian
AU  - Etz C
FAU - Schmidt, Christoph
AU  - Schmidt C
FAU - Wenzelburger, Frauke
AU  - Wenzelburger F
FAU - Wilhelm, Markus
AU  - Wilhelm M
FAU - Rothenburger, Markus
AU  - Rothenburger M
FAU - Drees, Gabi
AU  - Drees G
FAU - Scheld, Hans H
AU  - Scheld HH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - MU72812GK0 (Creatine)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Adult
MH  - Bilirubin/blood
MH  - Creatine/blood
MH  - Female
MH  - Heart Failure/mortality/*therapy
MH  - Heart Transplantation
MH  - Heart-Assist Devices/adverse effects
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Male
MH  - Middle Aged
MH  - Prosthesis Implantation
MH  - Thromboembolism/etiology
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/*therapy
EDAT- 2005/09/07 09:00
MHDA- 2006/05/31 09:00
CRDT- 2005/09/07 09:00
PHST- 2004/02/16 00:00 [received]
PHST- 2004/08/26 00:00 [revised]
PHST- 2004/08/31 00:00 [accepted]
PHST- 2005/09/07 09:00 [pubmed]
PHST- 2006/05/31 09:00 [medline]
PHST- 2005/09/07 09:00 [entrez]
AID - S1053-2498(04)00461-9 [pii]
AID - 10.1016/j.healun.2004.08.024 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2005 Sep;24(9):1188-94. doi: 
      10.1016/j.healun.2004.08.024.